Merck & Co. Inc., of Whitehouse Station, N.J., said the data monitoring committee for the Phase II/III EPOCH study testing MK-8931, an oral beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, in mild to moderate Alzheimer’s disease recently completed its planned interim safety analysis and recommended that the study continue to recruit patients with no changes to protocol.